NCCN: Continuing Education Accreditation Statement This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer. There is no fee for this article. No commercial
Search Results
Quality Indicators in the Management of Bladder Cancer
Jeffrey S. Montgomery, David C. Miller, and Alon Z. Weizer
Advocating for Equity in Cancer Care
James McCanney, Terrell Johnson, Lindsey A.M. Bandini, Shonta Chambers, Lynette Bonar, and Robert W. Carlson
How social determinants contribute to individual health and health equity has been the focus of recent research and increasing consensus. In cancer care, health outcomes are influenced by a variety of socioeconomic factors, including race
Barriers to Clinical Trial Participation as Perceived by Oncologists and Patients
Neal J. Meropol, Joanne S. Buzaglo, Jennifer Millard, Nevena Damjanov, Suzanne M. Miller, Caroline Ridgway, Eric A. Ross, John D. Sprandio, and Perry Watts
This project was supported by the Pennsylvania Department of Health (ME# 02-285), the National Institutes of Health (R01 82085), and the Fox Chase Cancer Center Behavioral Research Core Facility and Population Studies Facility (P30CA06927
Involving Family and Social Support Systems in Tobacco Cessation Treatment for Patients With Cancer
The Cancer Center Cessation Initiative Family and Social Support Systems Working Group
Engaging Family and Social Support Systems in Tobacco Cessation in Cancer Care A cancer diagnosis and treatment are stressful life events, both physically and mentally. Social support provided by informal caregivers, family, and friends is
The Economic Impact of Non-Melanoma Skin Cancer: A Review
Tejaswi Mudigonda, Daniel J. Pearce, Brad A. Yentzer, Phillip Williford, and Steven R. Feldman
N on-melanoma skin cancers (NMSCs), characterized by malignant growth of the epithelial layer or external surface of the skin, are the most prevalent form of skin cancer in the United States. 1 Since the 1960s, the incidence of NMSC has increased
Bladder Cancer
The UNMC Eppley Cancer Center at The Nebraska Medical Center
An estimated 61,420 new cases of urinary bladder cancer will be diagnosed in the United States in 2006, making it the fourth most common cancer in men and the ninth most common neoplasm in women. Because the median age of diagnosis is 65 years, medical comorbidities are a frequent consideration. The clinical spectrum of bladder cancer can be divided into 3 categories: noninvasive tumors, invasive lesions, and metastatic lesions. These categories differ in prognosis, management, and therapeutic goals, and these guidelines discuss management strategies to achieve the best possible outcomes.
For the most recent version of the guidelines, please visit NCCN.org
Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study
Firas Abdollah, Jesse D. Sammon, Kaustav Majumder, Gally Reznor, Giorgio Gandaglia, Akshay Sood, Nathanael Hevelone, Adam S. Kibel, Paul L. Nguyen, Toni K. Choueiri, Kathy J. Selvaggi, Mani Menon, and Quoc-Dien Trinh
Prostate cancer (PCa) is the most common noncutaneous cancer and the second leading cause of cancer-related death in North American men. 1 In the United States, 233,000 new cases of PCa are estimated to be diagnosed in 2014, along with 29,480 PCa
The Management of Patients With Stage IIIA Non–Small Cell Lung Cancer With N2 Mediastinal Node Involvement
Renato G. Martins, Thomas A. D’Amico, Billy W. Loo Jr, Mary Pinder-Schenck, Hossein Borghaei, Jamie E. Chaft, Apar Kishor P. Ganti, Feng-Ming (Spring) Kong, Mark G. Kris, Inga T. Lennes, and Douglas E. Wood
The management of patients with stage IIIA (N2) non–small cell lung cancer (NSCLC) remains the most challenging domain in thoracic oncology, and the use of evidence-based treatment guidelines is essential. 1 Notwithstanding improvements in the
Impact of Incident Cancer on Short-Term Coronary Artery Disease–Related Healthcare Expenditures Among Medicare Beneficiaries
Ishveen Chopra, Malcolm D. Mattes, Patricia Findley, Xi Tan, Nilanjana Dwibedi, and Usha Sambamoorthi
may develop new conditions. The most common preexisting or existing conditions in patients with CAD include cancer, hypertension, diabetes, and other cardiovascular diseases. 5 For these individuals, CAD-related expenditures can be higher than for
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass
Overview An estimated 174,650 new cases of prostate cancer will be diagnosed in 2019, accounting for 20% of new cancer cases in men. 1 The age-adjusted death rates from prostate cancer have declined 51% from 1993 to 2016. 1 Researchers have
